PF-Atlas › Clinical Trials › NCT06422884
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis
ENV-101 · Phase 2
Registry ID
NCT06422884
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
ENV-101
Sponsor
Endeavor Biomedicines, Inc.
Start
2024-11-15
Enrollment
213
Locations
78
About this trial
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06422884 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.